EBMT 2023 | CIMON trial update: pooled fecal microbiotherapy in patients with AML after intensive chemotherapy
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on evidence demonstrating the impact of the microbiome on patient outcomes before and after allogeneic transplantation, highlighting the results of the Phase I CIMON trial (NCT04150393), which investigated the safety and efficacy of oral pooled fecal microbiotherapy in restoring the gut microbiota of patients with acute myeloid leukemia (AML) who have received intensive chemotherapy. The study reported that this treatment was safe and helped restore the gut microbiome, and was particularly effective at a dosage of three capsules per day. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Therakos/Mallinckrodt: Honoraria; Sanofi: Honoraria; Astellas: Honoraria; JAZZ pharmaceuticals: Honoraria; Biocodex: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Celgene-BMS: Honoraria.
